| Literature DB >> 15452687 |
Mourad Ogbi1, Christopher J Wingard, Safia Ogbi, John A Johnson.
Abstract
We have observed a lengthening of the duration between spontaneous cardiac contractions under conditions that preferentially activate the epsilon protein kinase C (epsilonPKC) isozyme. Therefore, we investigated whether this response could be selectively mediated by epsilonPKC in neonatal cardiac myocytes (NCMs) and adult rat ventricular trabeculae. Contraction of NCMs was monitored using light scattering techniques and trabecular force generation was monitored in tissue baths using a force transducer. The involvement of the epsilonPKC isozyme was confirmed using an epsilonPKC-selective translocation inhibitor and Western blot translocation assays. In NCMs 3 nM 4-beta phorbol 12-myristate-13-acetate (PMA) treatment preferentially activates (translocates) epsilonPKC. In this study 3 nM 4-beta PMA induced a 2-fold increase in contractile amplitude and a approximately 14-fold increase in the quiescent period between contractions in NCMs. Extracellular adenosine 5'-triphosphate (ATP) also enhanced contractile amplitude by 1.7-fold and the quiescent period duration by 8-fold. The enhancement of quiescent period duration was attenuated by an epsilonPKC-selective translocation inhibitor. To investigate these relationships in intact myocardium, we studied spontaneously beating adult rat ventricular trabecula. In these fibers contractile amplitude was only modestly enhanced; however, the quiescent period was lengthened by 4.5-fold following a 15-min exposure to 3 nM 4-beta PMA. 4-beta PMA treatment also promoted arrhythmogenesis and increased the association of epsilonPKC with the particulate fraction in these fibers. Our results suggest that epsilonPKC may influence a specific phase of ventricular myocyte spontaneous beating. A better understanding of epsilonPKC modulation of spontaneous cardiac contraction may improve our understanding of the molecular events contributing to ventricular automaticity.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15452687 DOI: 10.1007/s00210-004-0979-5
Source DB: PubMed Journal: Naunyn Schmiedebergs Arch Pharmacol ISSN: 0028-1298 Impact factor: 3.000